AI-driven platform for Screening and behavioral treatment of children with Autism spectrum disorder by Manu Kohli, CEO, CogniAble

“The population in India for newborn every year is 18 million, so we have given the observation power of detecting the child's growth, especially on autism features to artificial intelligence base model,” Manu Kohli, CEO, CogniAble.

     Autism, or autism spectrum disorder (ASD), refers to a broad range of conditions characterized by challenges with social skills, repetitive behaviors, speech, and nonverbal communication. Currently, one in 500 people is diagnosed with autism in India, which translates to 0.2 percent of the population.

Manu Kohli, CEO, CogniAble is a certified Project management professional (PMP) with 16 years of Global SAP Implementation and Data Analytics experience. He has authored various papers in renowned journals and books with SAP PRESS. He is also pursuing an industry-sponsored Ph.D. from IIT - Delhi integrating Enterprise applications such as SAP and Machine Learning, Artificial Intelligence, and Network Sciences.

CogniAble is an AI-driven platform for Screening and behavioral treatment of children on Autism and Associated Disorders

CogniAble for screening autism spectrum disorder

Manu explains, “At CogniAble, we are developing artificial intelligence-based solutions for early detection, and then the intervention of children with the autism spectrum disorder. Autism is like an epidemic, before Corona, it was in the limelight. Autism is impacting one and a half to two children out of hundreds, so to make sure that you manage autism well, there is a need to detect these children very early. By detection, it means that every child that is born needs to be checked if he's growing properly, and he doesn't have the symptoms of autism or any other neurodevelopment delay. Since the population in India for newborns every year is 18 million, it is difficult to screen each child unless you have a technology-based solution. So what we are doing is, we have given the observation power of detecting the child's growth, especially on autism features to an artificial intelligence base model, where a parent or caregiver is interacting with a child in a natural setting and that session is video recorded and then that video is analyzed by an AI engine which then suggests if the child is on a risk of autism or not, if there is a delayed response observed or some features that are detected, so as to start intervention services immediately, from any remote location through a click of a button on a mobile phone. These services are very affordable and accessible. It comes with the complete protocol assessment of plans, all-digital in nature and all remotely executed,” he says.

Notion for the foundation of CogniAble

Manu sheds light on the subject, “There were two reasons for laying the foundation of CogniAble, my wife is a special educator, and when we got married in 2002, I got a chance to see special needs children which I never had experienced before. The second was, after six years of marriage, we recognized that our child was having a neurodevelopment delay and the detection was delayed because of some unforeseen reasons. But then that really motivated us to start something which can be meaningful for a lot of other parents like us who do not have those support services available,” he says.

A team that we stitched over a period of time

Manu talks on CogniAble being founded by researchers and scientists from IIT Delhi, pediatricians, psychologists from India and the USA to find affordable, accessible and high-quality management on autism condition, “For us to make that kind of solution that has a global impact and a meaningful scientific validation; you really need to have the academic pediatricians and academic scientists behind it to do that. So, I was pursuing my Ph.D. at IIT Delhi after I returned to India and my Ph.D. is focused on this topic only. So, I was very fortunate to get in touch with a few scientists and few professors from IIT Delhi in artificial intelligence, with which we piloted the solution initially and saw a lot of success. We then went to the government with our results, and the government was very, generous and supportive of our cause and funded us for a clinical trial in which we got hold of some of our partners like Dr. Monica Juneja from Maulana Azad Medical College, who is somebody who comes with a lot of experience in the autism world. And another co-founder I got was from the US, Dr. Josh, who runs multiple autism centers there. So it was a team that we stitched over a period of time. Our solution is in the clinical trial and our market price, once we take them for detection, can be done in less than Rs. 200/- which would be cost-saving for parents and families who come from Bihar, Odisha, Patna, or North-East to Delhi to get their child checked. They end up spending thousands of rupees for multiple sittings with the pediatricians. All this can happen virtually and especially with Corona, digital healthcare is anyways budding and it is available at an affordable cost. The same thing is for intervention as well, because intervention usually costs Rs. 30 to 40,000/- a month, with our tool, it will probably drop to Rs. 1500 – 2000/- a month. So that's the cost reduction and the quality we are bringing in and then the parents and child’s data is going to drive this therapy, which is the most unique thing about it,” he says.

Education and healthcare need a technological transformation

Manu shares his thoughts on IoT and AI being the future of healthcare, “I think it is inevitable, though technology and artificial intelligence coming into education and healthcare, I think these two sectors really need a technology transformation because of its limited access and also because of the cost. I think these two sectors are really going to see a lot of focus and introduction of technology like artificial intelligence, and especially after COVID as post-COVID, the adoption of this process has accelerated. Because right now we have experienced that we can work remotely and opt for digital healthcare. But I think once you start, bringing in the database decision making into telehealth, that's going to be a game-changer not only for traditional healthcare like fever but even the mental health issues like depression, autism, or dementia. So these are all going to be probably handled, and artificial intelligence will have a very large role to play in here,” he says.

(Edited by Rabia Mistry Mulla)

 

Contributed By: Manu Kohli, CEO, CogniAble
Tags : #medicircle #smitakumar #manukohli #cogniable #autism #autistic #learningdisabilities #neurodevelopmental #autismfeatures #ai

About the Author


Rabia Mistry Mulla

'For vessels to change their course, they have to be hit by a strong wind first!'
So here I am penning down my thoughts on health and research after 6 years of planning Diets.
Being a Clinical Dietitian & a Diabetes Educator I always had a thing for writing, alas, been hit by the winds towards a new course!
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

BioNTech and Fosun Pharma announce the start of phase 2 clinical trial of COVID-19 Vaccine in ChinaNovember 25, 2020
1,031 new cases of COVID-19 confirmed in Himachal PradeshNovember 25, 2020
Cooking with wood may cause lung damageNovember 25, 2020
More than 56 lakh sample tests for COVID-19 conducted in OdishaNovember 25, 2020
COVID-19 recovery rate in Bihar improves to 97.30 pctNovember 25, 2020
Green Mediterranean (‘green Med’) diet may be even better for healthNovember 25, 2020
Chhattisgarh: Intensive Covid screening of all passengers to be done mandatorily at airportsNovember 25, 2020
New guidance issued on policies to protect populations in vulnerable situations in context of COVID-19November 25, 2020
Life Extension® Launches Bloat Relief Formula.November 25, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR TestingNovember 25, 2020
Bristol Myers Squibb Receives European Commission Approval for OpdivoNovember 25, 2020
QualTex Laboratories adds Ortho Diagnostics VITROS® Anti-SARS-CoV-2 IgG assayNovember 25, 2020
China resorts to rigorous measures after multiple locally transmitted coronavirus cases detected in three citiesNovember 25, 2020
National COVID-19 recovery rate reaches 93.72 pctNovember 25, 2020
Nearly 11,60,000 COVID samples tested in country in last 24 hoursNovember 25, 2020
Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysisNovember 25, 2020
Taking the Pill may cut risk of severe asthma bouts in women of reproductive ageNovember 25, 2020
Multilateral cooperation is key to overcoming global challenges such as COVID-19: Dr Harsh VardhanNovember 25, 2020
Polaryx Therapeutics receives both rare pediatric disease and orphan drug designations from US FDANovember 25, 2020
Panaxia and Neuraxpharm expand strategic collaboration to France with medical cannabisNovember 25, 2020